Is it too early to recommend local treatment in oligometastatic non-small cell lung cancer: a plea for equipoise.

Autor:	Ahmad I; Department of Radiation Oncology, Rajiv Gandhi Cancer Institute & Research Centre, New Delhi 110085, India., Chufal KS; Department of Radiation Oncology, Rajiv Gandhi Cancer Institute & Research Centre, New Delhi 110085, India., Miller AA; Department of Radiation Oncology, Illawarra Cancer Care Center, NSW 2500, Australia., Bajpai R; School of Medicine, Keele University, Staffordshire ST5 5BG, United Kingdom., Umesh P; Department of Radiation Oncology, Rajiv Gandhi Cancer Institute & Research Centre, New Delhi 110085, India., Dawer A; Jindal Global Law School, OP Jindal Global University, Haryana 131001, India., Tandon S; Department of Radiation Oncology, Rajiv Gandhi Cancer Institute & Research Centre, New Delhi 110085, India., Gandhidasan S; Department of Radiation Oncology, Illawarra Cancer Care Center, NSW 2500, Australia., Dua B; Department of Radiation Oncology, Venkateshwar Hospital, New Delhi 110078, India., Bhatia K; Department of Radiation Oncology, Rajiv Gandhi Cancer Institute & Research Centre, New Delhi 110085, India., Gairola M; Department of Radiation Oncology, Rajiv Gandhi Cancer Institute & Research Centre, New Delhi 110085, India.
Jazyk:	angličtina
Zdroj:	The British journal of radiology [Br J Radiol] 2024 May 07; Vol. 97 (1157), pp. 913-919.
DOI:	10.1093/bjr/tqae068
Abstrakt:	Oligometastatic non-small cell lung cancer (OMD NSCLC) has been proposed to bridge the spectrum between non-metastatic and widely metastatic states and is perceived as an opportunity for potential cure if removed. Twelve clinical trials on local treatment have been reported, yet none are conclusive. These trials informed the development of a joint clinical practice guideline by the American & European Societies for Radiation Oncology, which endorses local treatment for OMD NSCLC. However, the heterogeneity between prognostic factors within these trials likely influenced outcomes and can only support guidance at this time. Caution against an uncritical acceptance of the guideline is discussed, as strong recommendations are offered based on expert opinion and inconclusive evidence. The guideline is also examined by a patient's caregiver, who emphasizes that uncertain evidence impedes shared decision making. (© The Author(s) 2024. Published by Oxford University Press on behalf of the British Institute of Radiology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu